Breakthroughs and ViewsRole of Smad4 (DPC4) inactivation in human cancer
Section snippets
Isolation of the DPC4 gene and its identification as a member of the Smad family
Smad4 was first identified as a tumor suppressor gene of pancreatic cancer by Harn et al. in 1996 and designated as DPC4 (homozygously deleted in pancreatic carcinoma, locus 4) [1]. Nearly 90% of pancreatic cancer show loss of heterozygosity (LOH) at chromosome 18q [2], in which the candidate tumor suppressor gene DCC (deleted in colorectal carcinoma) is located. Since mutation of the DCC gene has not been found in pancreatic and other cancers, a search for a novel target gene of the 18qLOH was
Smad proteins and TGFβ signaling
Smad proteins are the critical components of the TGFβ signaling pathway, which negatively regulates the growth of epithelial cells (for a review see [4]). As illustrated in Fig. 1, TGFβ signals are transduced by two kinds of receptors, Receptor I and II, which have serine/threonine kinase activity. Upon the binding of TGFβ to TGFβRII, this receptor activates TGFβRI by phosphorylation. TGFβRI in turn phosphorylates the intracellular target Smad2 or Smad3. These proteins have an SSXS motif in
Germline mutation of the Smad4 gene in familial juvenile polyposis
Familial juvenile polyposis is an autosomal dominant disease characterized by predisposition to hamartomatous polyps and gastrointestinal cancer. This disease usually occurs during childhood. In 1998, Howe et al. [7] reported germline mutations in the Smad4 gene among 5 of 9 familial juvenile polyposis families, suggesting that Smad4 is the causative gene of this disease. To date, germline mutations have been detected in nearly 20 families and account for 25–60% of the cases analyzed. The
Somatic alterations of the Smad4 gene in pancreatic cancer
Prior to isolation of the DPC4 gene, the same group demonstrated in 1995 frequent LOH at chromosomes 1p (70%), 9p (80%), 17p (90%), and 18q (90%) by an allelotype analysis of 18 xenografts of human pancreatic cancer [2]. This suggested that possible tumor suppressor genes are present in these regions. As mentioned above, the tumor suppressor gene, Smad4, was identified at the homozygously deleted region 18q21.1. Additional genetic alterations in pancreatic cancer include mutations of the K-ras
Somatic alterations of the Smad4 gene in colorectal cancer
In 1990, Fearon and Vogelstein [15] proposed multi-stage genetic alterations in colorectal carcinogenesis, typically in an adenoma–carcinoma sequence. In this sequence, the APC gene (5q) is inactivated at an early stage, followed by activation of the K-ras gene during the development of moderate to severe adenoma, and inactivation of the p53 gene (17p) at the stage of conversion from adenoma to carcinoma. Additional frequent LOH at chromosomes 1p, 8p, 18q, and 22q suggests that inactivation of
Somatic alterations of the Smad4 gene in various types of human cancer
Table 1 summarizes the Smad4 gene alterations in various human cancers. Somatic alteration of the Smad4 gene is, as mentioned above, most prevalent in pancreatic and colorectal cancer. Intragenic mutations were less frequently observed in acute myeloid leukemia, biliary tract carcinoma, ovarian cancer, and small intestinal carcinoma, and occasionally in gastric carcinoma, head/neck squamous carcinoma, hepatocellular carcinoma, and lung carcinoma.
As shown in Fig. 3, the majority of Smad4 gene
Mutations of other members of the Smad family
Mutations of the Smad2 gene, located at 18q21, have been detected in the MH2 domain in colorectal and other human cancers, but their frequency being far less than those of the Smad4 gene [37]. Mutations of Smad3 (15q21), Smad6 (15q21), and Smad7 (18q21) genes have not been detected so far in human cancers.
References (37)
- et al.
TGFβ signalling in growth control, cancer, and heritable disorders
Cell
(2000) - et al.
Comprehensive analysis of SMAD4 mutations and protein expression in juvenile polyposis. Evidence for a distinct genetic pathway and polyp morphology in SMAD4 mutation carriers
Am. J. Pathol.
(2001) - et al.
Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic adenocarcinomas
Am. J. Pathol.
(2000) - et al.
A genetic model for colorectal tumorigenesis
Cell
(1990) - et al.
Familial polyposis: recent advances
Crit. Rev. Oncol./Hematol.
(1995) - et al.
Somatic alterations of the DPC4 gene in human colorectal cancers in vivo
Gastroenterology
(1996) - et al.
Inactivation of both alleles of the DPC4/SMAD4 gene in advanced colorectal cancers: identification of seven novel somatic mutations in tumors from Japanese patients
Mut. Res.
(1999) - et al.
Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease
Am. J. Pathol.
(2000) - et al.
Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes
Cell
(1998) - et al.
MADR2 maps 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma
Cell
(1996)